Santourlidis Simeon, Araúzo-Bravo Marcos J, Erichsen Lars, Bendhack Marcelo L
Institute of Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Group of Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, 20014 San Sebastián, Spain.
Cancers (Basel). 2024 May 20;16(10):1941. doi: 10.3390/cancers16101941.
Based on the impressive success of Car-T-cell therapy in the treatment of hematological malignancies, a broad application for solid tumors also appears promising. However, some important hurdles need to be overcome. One of these is certainly the identification of specific target antigens on cancer cells. Hypomethylation is a characteristic epigenetic aberration in many tumor entities. Genome-wide screenings for consistent DNA hypomethylations in tumors enable the identification of aberrantly upregulated transcripts, which might result in cell surface proteins. Thus, this approach provides a new perspective for the discovery of potential new Car-T-cell target antigens for almost every tumor entity. First, we focus on this approach as a possible treatment for prostate cancer.
基于嵌合抗原受体T细胞（Car-T）疗法在治疗血液系统恶性肿瘤方面取得的显著成功，其在实体瘤中的广泛应用似乎也前景广阔。然而，一些重要的障碍仍需克服。其中之一无疑是识别癌细胞上的特异性靶抗原。低甲基化是许多肿瘤实体中的一种特征性表观遗传畸变。对肿瘤中一致的DNA低甲基化进行全基因组筛查，能够识别异常上调的转录本，这些转录本可能产生细胞表面蛋白。因此，这种方法为几乎每个肿瘤实体发现潜在的新Car-T细胞靶抗原提供了新视角。首先，我们将重点关注这种方法作为前列腺癌的一种可能治疗手段。
